Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma - Report - MDSpire

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

  • By

  • Jack Y. Ghannam

  • Julian Bryan

  • Jakob Weiss

  • Daniel Kovarsky

  • David Merrell

  • Conor Messer

  • Kristy Schlueter-Kuck

  • Geoffrey G. Fell

  • Mary Jane Lim-Fat

  • Gilbert Youssef

  • Rifaquat Rahman

  • Lei Qin

  • Geoffrey S. Young

  • J. Thomas Janes

  • McKayla Van Orden

  • Kathleen L. Pfaff

  • Andrew Gans

  • Emma S. Lin

  • Raymond Y. Huang

  • Brian P. Danysh

  • Laxmi Parida

  • Shuqiang Li

  • Patrick Y. Wen

  • E. Antonio Chiocca

  • Donna Neuberg

  • Keith L. Ligon

  • Itay Tirosh

  • David A. Reardon

  • Gad Getz

  • Catherine J. Wu

  • June 12, 2026

  • 0 min

Share

Clinical Report: Correction Notice on Tumor Transcriptional Profiles in Glioblastoma

Overview

This correction notice addresses inaccuracies in the original publication regarding tumor transcriptional profiles in glioblastoma patients undergoing immune checkpoint inhibition. Key corrections include clarifications on sample profiling and statistical data.

Background

Glioblastoma is the most common and aggressive primary brain tumor in adults, with current immunotherapy approaches failing to meet survival benchmarks in clinical trials. Identifying biomarkers for patient selection in immunotherapy is crucial for improving treatment outcomes and understanding tumor behavior.

Data Highlights

No new numerical data presented in the correction notice.

Key Findings

  • Correction of sample profiling method from 'bulk DNA sequencing' to 'bulk DNA sequencing cases'.
  • Correction of hazard ratio confidence interval from '0.90–2.40' to '0.92–2.40'.
  • Correction of figure title from 'SOX2' to 'SOX2high'.
  • Emphasis on the importance of accurate reporting in clinical research.
  • Highlighting the need for ongoing research into biomarkers for glioblastoma treatment.

Clinical Implications

Accurate reporting of clinical trial data is essential for guiding treatment decisions in glioblastoma. Clinicians should remain aware of the evolving landscape of biomarkers that may influence immunotherapy outcomes.

Conclusion

The corrections made in this notice are vital for maintaining the integrity of research findings in glioblastoma treatment. Continued scrutiny and validation of biomarkers are necessary for advancing patient care.

Related Resources & Content

  1. Nature Cancer, 2026 -- Correction Notice: Prognostic Value of Tumor Transcriptional Profiles in Glioblastoma Patients Undergoing Immune Checkpoint Inhibition
  2. Frontiers in Immunology — Biomarkers for predicting immunotherapy response and resistance in glioblastoma
  3. Acta Neuropathologica — Immune Profiling in Glioblastoma Reveals an Inflammatory Perivascular Subtype Linked to Improved Survival Outcomes
  4. asco ai in oncology — Transcriptomic Classifier for Predicting Neoadjuvant Immunotherapy Response in Triple-Negative Breast Cancer
  5. Journal of Neuro-Oncology — Immunological Biomarkers in Patients with Newly Diagnosed Glioblastoma Treated with the Stupp Protocol Following Neurosurgery: A Retrospective Analysis
  6. Biomarkers for predicting immunotherapy response and resistance in glioblastoma
  7. Immune Profiling in Glioblastoma Reveals an Inflammatory Perivascular Subtype Linked to Improved Survival Outcomes
  8. Transcriptomic Classifier for Predicting Neoadjuvant Immunotherapy Response in Triple-Negative Breast Cancer
  9. Immunological Biomarkers in Patients with Newly Diagnosed Glioblastoma Treated with the Stupp Protocol Following Neurosurgery: A Retrospective Analysis
  10. EANS-EANO guidelines on the extent of resection in gliomas
  11. Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma | Nature Cancer
  12. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update  

Original Source(s)

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

  • by Jack Y. Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G. Fell, Mary Jane Lim-Fat, Gilbert Youssef, Rifaquat Rahman, Lei Qin, Geoffrey S. Young, J. Thomas Janes, McKayla Van Orden, Kathleen L. Pfaff, Andrew Gans, Emma S. Lin, Raymond Y. Huang, Brian P. Danysh, Laxmi Parida, Shuqiang Li, Patrick Y. Wen, E. Antonio Chiocca, Donna Neuberg, Keith L. Ligon, Itay Tirosh, David A. Reardon, Gad Getz, Catherine J. Wu

  • June 12, 2026

Related Content

Primary large cell neuroendocrine carcinoma of the breast with metastasis in the lymph nodes: a case report and literature review

Coexistence of rectal adenocarcinoma and rectal and lymph node tuberculosis: a case report with a limited narrative review

Editorial: Exploring unconventional T cells and CAR-T-cells in cancer immunotherapy